Updates on Non-Statin LDL-Lowering Therapy

Research output: Contribution to journalArticlepeer-review


Purpose of Review: There is ample evidence of the benefits and safety of low-density lipoprotein (LDL)-lowering therapies in the prevention of atherosclerotic cardiovascular disease. While statins remain the first-line agent for LDL reduction, several new therapies are now available. This narrative review provides an overview of currently available non-statin LDL-lowering agents, specifically mechanisms of action and data on efficacy and safety. It also discusses recommendations on their use in clinical practice. Recent Findings: Ezetimibe, PCSK9 inhibitors, and bempedoic acid have proven safe and efficacious in reducing cardiovascular events in large randomized controlled trials. Inclisiran is a promising agent that suppresses PCSK9 mRNA translation and is currently under investigation in a large clinical outcomes randomized controlled trial assessing its effect on clinical outcomes. Summary: Expert consensus advocates for lower LDL targets in higher risk patients and escalation to or a combination of non-statin therapies as needed to achieve these goals.

Original languageEnglish (US)
Pages (from-to)221-231
Number of pages11
JournalCurrent Cardiology Reports
Issue number4
StatePublished - Apr 2024


  • Bempedoic acid
  • Ezetimibe
  • Hyperlipidemia
  • Inclisiran
  • Low-density lipoprotein
  • Proprotein convertase subtilisin/kexin type 9 inhibitor

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Updates on Non-Statin LDL-Lowering Therapy'. Together they form a unique fingerprint.

Cite this